The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
Open accessAbstract
OBJECTIVE: To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment. METHODS: A phase 2, exploratory, randomized, double-blind, placebo-controlled, 15-center study is described. Eligible patients were randomly assigned (1:1) to receive 4 doses over a 3-week period of either 10 mg/kg IV efgartigimod or matched placebo combined with their standard-of-care therapy. Primary endpoints were safety and tolerability. Secondary endpoints included efficacy (change from baseline to week 11 of Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis, and Myasthenia Gravis Composite disease severity scores, and of the revised 15-item Myasthenia Gravis Quality of Life scale), pharmacokinetics, pharmacodynamics, and immunogenicity. RESULTS: Of the 35 screened patients, 24 were enrolled and randomized: 12 received efgartigimod and 12 placebo. Efgartigimod was well-tolerated in all patients, with no serious or severe adverse events reported, no relevant changes in vital signs or ECG findings observed, and no difference in adverse events between efgartigimod and placebo treatment. All patients treated with efgartigimod showed a rapid decrease in total immunoglobulin G (IgG) and anti-AChR autoantibody levels, and assessment using all 4 efficacy scales consistently demonstrated that 75% showed a rapid and long-lasting disease improvement. CONCLUSIONS: Efgartigimod was safe and well-tolerated. The correlation between reduction of levels of pathogenic IgG autoantibodies and disease improvement suggests that reducing pathogenic autoantibodies with efgartigimod may offer an innovative approach to treat MG. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Self-citationInternational consensus guidance for management of myasthenia gravis: Executive summary
Sanders, D. B., Wolfe, G. I., Benatar, M., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N., Massey, J. M., Melms, A., Murai, H., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002790 · Cited by 1,212
Self-citationGilhus, N. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1602678 · Cited by 1,048
Howard, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Self-citationMyasthenia gravis activities of daily living profile
Wolfe, G. I., Herbelin, L., Nations, S. P., Foster, B., Bryan, W. W., & Barohn, R. J. (1999) · Neurology · doi:10.1212/wnl.52.7.1487 · Cited by 572
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427
Self-citationReliability Testing of the Quantitative Myasthenia Gravis Scorea
BAROHN, R. J., McINTIRE, D., HERBELIN, L., WOLFE, G. I., NATIONS, S., & BRYAN, W. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11015.x · Cited by 417
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Self-citation
Cited by
Howard, J. F., Bril, V., Vu, T., Karam, C., Peric, S., Margania, T., Murai, H., Bilinska, M., Shakarishvili, R., Smilowski, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00159-9 · Cited by 739
Self-citationMyelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Autoantibodies in neurological disease
Prüss, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00543-w · Cited by 319
Bril, V., Drużdż, A., Grosskreutz, J., Habib, A. A., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vissing, J., Vu, T., Boehnlein, M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00077-7 · Cited by 295
Self-citation
Metadata
- Authors
- Howard, J. F., Bril, V., Burns, T. M., Mantegazza, R., Bilinska, M., Szczudlik, A., Beydoun, S., Garrido, F. J. R. D. R., Piehl, F., Rottoli, M., Van Damme, P., Vu, T., Evoli, A., Freimer, M., Mozaffar, T., Ward, E. S., Dreier, T., Ulrichts, P., Verschueren, K., Guglietta, A., de Haard, H., Leupin, N., Verschuuren, J. J. G. M., on behalf of the Efgartigimod MG Study Group, on behalf of the Efgartigimod MG Study Group, Claeys, K., Mathew, V., Sgarzi, M., Diez Tejedor, E., Harvey, B. L., Farias, J., Frangiomore, R., Heintsman, S., de Meel, R., Chopra, M., Emilio Alboini, P., & Genge, A.
- Venue
- Neurology
- Published
- 2019-06-04
- Volume
- 92
- Issue
- 23
- Pages
- e2661-e2673
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2944937742
- Cited by
- 296
- References
- 20
- FWCI
- 18.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. https://app.cochat.ai/papers/10.1212/wnl.0000000000007600
- The paper
- Howard, J. F., Bril, V., Burns, T. M., Mantegazza, R., Bilinska, M., Szczudlik, A., Beydoun, S., Garrido, F. J. R. D. R., Piehl, F., Rottoli, M., Van Damme, P., Vu, T., Evoli, A., Freimer, M., Mozaffar, T., Ward, E. S., Dreier, T., Ulrichts, P., Verschueren, K., . . . Genge, A. (2019). Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. https://doi.org/10.1212/wnl.0000000000007600
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.